Short answer
Strata Critical Medical, Inc. (SRTA) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $74M (up 1311.9% year over year) with net income of −$8M.
Q3 2026 key financials · XBRL
- Revenue
- $74M
- +1311.9% YoY · +2.2% QoQ
- Net income
- −$8M
- −113.3% YoY · +27.6% QoQ
- Operating margin
- -5.2%
- Gross margin
- 22.7%
- EPS (diluted)
- −$0.08
- −111.3% YoY · +38.5% QoQ
Source: XBRL data from the Strata Critical Medical, Inc. (SRTA) Q3 2026 10-Q on SEC EDGAR. USD.
Strata Critical Medical, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $74.1M, up 50.3% YoY from $49.3M, driven by Clinical revenue of $29.2M
- Total gross margin 22.7% vs 21.6% YoY, with Clinical margin 25.6% and Logistics margin 20.8%
- Best segment Clinical: $29.2M revenue and $7.5M gross profit, worst Logistics: $44.9M revenue, down 3.5% YoY
- Cash and equivalents $35.1M vs $31.0M, operating cash flow $19.0M vs $(40.6)M YoY
- $35.8M acquisition spending and $8.1M property investments, with $15.3M proceeds from Buyer Shares sales
- Outlook: $41.6M liquidity expected sufficient for current needs through 12 months, with donor supply flattening and clinician costs a headwind
Risk Factors
- No material changes to risks disclosed in the December 31, 2025 Form 10-K
- Carried-forward business risks could materially affect operations and financial condition
- Common-stock trading price risk from adverse business developments
- Forward-looking statement risk from actual results differing materially from expectations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Strata Critical Medical, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.